Judah Frommer
Stock Analyst at Morgan Stanley
(3.89)
# 622
Out of 5,245 analysts
193
Total ratings
62.5%
Success rate
5%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Maintains: Equal-Weight | $21 → $22 | $19.84 | +10.89% | 4 | May 14, 2026 | |
| CMPS COMPASS Pathways | Maintains: Overweight | $16 → $17 | $11.59 | +46.68% | 1 | May 14, 2026 | |
| BCAX Bicara Therapeutics | Maintains: Overweight | $36 → $37 | $20.84 | +77.54% | 2 | May 12, 2026 | |
| EVMN Evommune | Maintains: Overweight | $54 → $55 | $23.55 | +133.55% | 2 | May 11, 2026 | |
| KLRS Kalaris Therapeutics | Initiates: Overweight | $14 | $5.12 | +173.44% | 1 | Apr 16, 2026 | |
| IMMX Immix Biopharma | Initiates: Overweight | $20 | $8.67 | +130.68% | 1 | Mar 25, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $19 → $18 | $14.16 | +27.12% | 3 | Mar 18, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $18 → $17 | $6.75 | +151.85% | 4 | Mar 6, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $144.25 | +39.34% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $10.88 | +157.35% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Equal-Weight | $34 | $27.05 | +25.69% | 1 | Feb 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $101 → $145 | $124.03 | +16.91% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $30.58 | +40.61% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $8.69 | -30.96% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $1.75 | +71.43% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $0.8726 | +4,484.00% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.49 | +422.09% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $13.05 | +129.89% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $29.67 | -22.48% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $69.79 | -28.36% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $16.96 | +731.37% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.33 | +107.85% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $35.67 | -38.32% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $7.93 | -11.73% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $6.61 | +21.12% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $110.57 | -58.40% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.13 | +123.64% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $24.76 | +122.13% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $109.53 | -58.00% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $95.18 | -48.52% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,050.45 | -64.78% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $81.24 | -61.84% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $77.00 | -1.30% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $105.11 | +73.15% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $95.71 | +11.80% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $83.07 | +14.36% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $16.27 | +10.63% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $219.79 | -47.22% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $94.43 | -59.76% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $85.39 | -74.24% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.07 | -47.82% | 9 | Apr 29, 2020 |
Zenas BioPharma
May 14, 2026
Maintains: Equal-Weight
Price Target: $21 → $22
Current: $19.84
Upside: +10.89%
COMPASS Pathways
May 14, 2026
Maintains: Overweight
Price Target: $16 → $17
Current: $11.59
Upside: +46.68%
Bicara Therapeutics
May 12, 2026
Maintains: Overweight
Price Target: $36 → $37
Current: $20.84
Upside: +77.54%
Evommune
May 11, 2026
Maintains: Overweight
Price Target: $54 → $55
Current: $23.55
Upside: +133.55%
Kalaris Therapeutics
Apr 16, 2026
Initiates: Overweight
Price Target: $14
Current: $5.12
Upside: +173.44%
Immix Biopharma
Mar 25, 2026
Initiates: Overweight
Price Target: $20
Current: $8.67
Upside: +130.68%
Trevi Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $19 → $18
Current: $14.16
Upside: +27.12%
REGENXBIO
Mar 6, 2026
Maintains: Overweight
Price Target: $18 → $17
Current: $6.75
Upside: +151.85%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $144.25
Upside: +39.34%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $10.88
Upside: +157.35%
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $27.05
Upside: +25.69%
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $124.03
Upside: +16.91%
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $30.58
Upside: +40.61%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.69
Upside: -30.96%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.75
Upside: +71.43%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $0.8726
Upside: +4,484.00%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.49
Upside: +422.09%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $13.05
Upside: +129.89%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $29.67
Upside: -22.48%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $69.79
Upside: -28.36%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $16.96
Upside: +731.37%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.33
Upside: +107.85%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $35.67
Upside: -38.32%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $7.93
Upside: -11.73%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $6.61
Upside: +21.12%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $110.57
Upside: -58.40%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.13
Upside: +123.64%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $24.76
Upside: +122.13%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $109.53
Upside: -58.00%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $95.18
Upside: -48.52%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,050.45
Upside: -64.78%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $81.24
Upside: -61.84%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $77.00
Upside: -1.30%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $105.11
Upside: +73.15%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $95.71
Upside: +11.80%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $83.07
Upside: +14.36%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $16.27
Upside: +10.63%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $219.79
Upside: -47.22%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $94.43
Upside: -59.76%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $85.39
Upside: -74.24%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.07
Upside: -47.82%